Original Source(s)
Related Content
FDA Approves New First-Line TNBC Regimen
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
June 26, 2026
-
3 min
Case Study: BRCA Mutation Led To Early Detection of Pre-Ovarian Cancer Condition
A 59-year-old woman was referred to Nicole Gaulin, MD, a gynecologic oncologist at Roswell Park Comprehensive Cancer Center, after learning she had a BRCA2 mutation linked with both breast cancer in a cousin and colon cancer in her father.
June 24, 2026
-
1 min
FDA Approves Gedatolisib in Breast Cancer
In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.
July 14, 2026
-
2 min